The global autoinjectors market is growing rapidly as more patients and healthcare providers adopt convenient and easy-to-use drug delivery devices. The market is projected to reach USD 300.46 billion by 2031, up from USD 127.30 billion in 2026, registering a CAGR of 18.7% from 2026 to 2031.

Autoinjectors are designed to make the administration of injectable medicines simpler. They are particularly useful for patients who need regular treatments for chronic and autoimmune diseases.

Download the PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

What Is Driving the Autoinjectors Market?

The increasing prevalence of chronic and autoimmune diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis is one of the major factors driving demand for autoinjectors.

Patients with chronic conditions may require frequent injections over long periods. Autoinjectors can make self-administration easier and more convenient, which can support treatment adherence.

The growing use of biologics and biosimilars is another important factor. As more injectable therapies become available, the need for convenient drug delivery systems is also increasing.

Regulatory approvals for autoinjector-based therapies, including treatments involving GLP-1 drugs, are further supporting market growth. These developments can help reduce the burden associated with frequent injections and encourage patients to manage treatments at home.

Growing Adoption of Self-Administration

Healthcare is increasingly moving toward patient-centered and self-administered treatment. Autoinjectors allow patients to administer certain medicines without requiring every dose to be given by a healthcare professional.

This can provide several benefits, including:

• Greater convenience for patients
• Reduced need for clinic visits
• Easier medication administration
• Improved treatment flexibility
• Better support for home-based care

Government initiatives and favorable reimbursement policies are also helping increase access to self-administered therapies.

Recent Industry Developments

The autoinjectors market is also being influenced by investments and partnerships across the pharmaceutical and healthcare industries.

In March 2026, Novo Nordisk announced an agreement with Hims & Hers Health to expand access to FDA-approved semaglutide medicines in the US. The agreement focuses on improving access to branded FDA-approved medicines through telehealth channels.

In another development, AbbVie invested USD 380 million in North Chicago to expand its API manufacturing facilities in the US. The planned facilities are expected to incorporate advanced manufacturing technologies and artificial intelligence, with construction beginning in spring 2026 and operations expected in 2029.

These developments highlight the growing focus on improving pharmaceutical manufacturing, access, and technology.

Key Players in the Autoinjectors Market

The autoinjectors market includes companies operating across both autoinjector devices and finished drug formulations.

Prominent players in autoinjector devices include:

• Becton, Dickinson and Company (US)
• SHL Medical (Switzerland)
• Ypsomed (Switzerland)

Leading companies in finished autoinjector formulations include:

• Novo Nordisk (Denmark)
• Eli Lilly and Company (US)
• AbbVie (US)

AbbVie

AbbVie is a global biopharmaceutical company involved in the development, manufacturing, and commercialization of innovative medicines.

Its portfolio covers areas such as immunology, oncology, aesthetics, neuroscience, and eye care. The company has operations across multiple regions, including North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East.

AbbVie’s investment in advanced manufacturing technologies and AI highlights its focus on strengthening pharmaceutical production capabilities.

Novo Nordisk

Novo Nordisk is a global healthcare company with a strong focus on treatments for chronic diseases. The company offers pharmaceutical products as well as drug delivery devices.

Its portfolio includes pens and needles, smart pens, devices, apps, and medicines. Novo Nordisk has a global presence and operates R&D centers across Asia Pacific, Europe, and North America.

The company’s strong position in diabetes and metabolic disease therapies supports its role in the growing self-administered drug delivery market.

Eli Lilly and Company

Eli Lilly and Company is a major pharmaceutical company developing and commercializing medicines across areas such as cardiometabolic health, oncology, immunology, and neuroscience.

The company operates across numerous international markets and has a broad global distribution network.

Its focus on innovative medicines and injectable therapies makes Eli Lilly an important participant in the development of convenient drug delivery solutions.

Market Ranking and Competitive Landscape

The autoinjectors market is relatively consolidated, with several major companies holding strong positions.

In the autoinjector devices segment, Becton, Dickinson and Company, SHL Medical, and Ypsomed are among the leading players.

In the finished autoinjector formulations segment, Novo Nordisk, Eli Lilly and Company, and AbbVie are prominent market participants.

These companies benefit from strong global distribution networks, established brands, advanced R&D capabilities, and partnerships with other healthcare organizations.

At the same time, smaller and regional companies are competing by developing cost-effective devices, innovative technologies, and specialized drug delivery solutions.

Future Outlook

The future of the autoinjectors market looks promising as healthcare continues to shift toward home-based treatment and self-administration.

The increasing use of biologics, biosimilars, GLP-1 therapies, and other injectable medicines is expected to create additional demand for convenient drug delivery devices.

Technological developments may also make autoinjectors smarter and easier to use. Features such as connectivity, dose tracking, digital health integration, and improved device ergonomics could further enhance the patient experience.

With the market projected to grow from USD 127.30 billion in 2026 to USD 300.46 billion by 2031, autoinjectors are expected to remain an important part of the evolving drug delivery landscape.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724